Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.51 USD | -8.53% | +140.60% | +120.93% |
May. 15 | BMO Capital Adjusts Price Target on Arcadium Lithium to $5.50 From $6, Maintains Market Perform Rating | MT |
May. 10 | Arcadium Lithium Applies to Cease to be a Reporting Issuer in Canada | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an enterprise value anticipated at 4.21 times the sales for the current fiscal year, the company turns out to be overvalued.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+120.93% | 4.76B | B+ | ||
+17.07% | 66.31B | A- | ||
-0.29% | 48.46B | A- | ||
+21.61% | 43.27B | B+ | ||
+26.72% | 27.41B | A- | ||
+9.25% | 19.26B | C+ | ||
+9.75% | 16.58B | B+ | ||
-2.14% | 16.61B | B+ | ||
-15.01% | 14.41B | C+ | ||
-30.22% | 14.02B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALTM Stock
- LTHM Stock
- Ratings LIVENT